Zyprexa Intramuscular
Categoria
Zyprexa Intramuscular Marchi, Zyprexa Intramuscular Analoghi
Zyprexa Intramuscular Marchi miscela
Zyprexa Intramuscular Formula chimica
C17H20N4S
Zyprexa Intramuscular RX link
http://www.rxlist.com/cgi/generic3/symbyax.htm
Zyprexa Intramuscular FDA foglio
Zyprexa Intramuscular DMS (foglio di materiale di sicurezza)
Zyprexa Intramuscular Sintesi di riferimento
Chakrabarti JK et al. US Pat. 5,229,382 (1991)
Zyprexa Intramuscular Peso molecolare
312.434 g/mol
Zyprexa Intramuscular Temperatura di fusione
195oC
Zyprexa Intramuscular H2O Solubilita
Nessuna informazione disponibile
Zyprexa Intramuscular Stato
Solid
Zyprexa Intramuscular LogP
2.199
Zyprexa Intramuscular Forme di dosaggio
Tablet (orale)
Zyprexa Intramuscular Indicazione
Per il trattamento della schizofrenia e psicosi maniaco-depressiva (disturbo bipolare).
Zyprexa Intramuscular Farmacologia
Olanzapina, un farmaco antipsicotico atipico, è usata per trattare sia i sintomi positivi e negativi della schizofrenia, mania acuta con disturbo bipolare, agitazione, sintomi psicotici e nella demenza. Futuro gli usi possono includere il trattamento del disturbo ossessivo-compulsivo e gravi disturbi comportamentali nell'autismo. Strutturalmente e farmacologicamente simile alla clozapina, olanzapina si lega per alfa (1), la dopamina, , H1 dell'istamina, muscarinici, e la serotonina di tipo 2 (5-HT2) recettori.
Zyprexa Intramuscular Assorbimento
Ben assorbito, con circa il 40% della dose è metabolizzato prima di raggiungere la circolazione sistemica.
Zyprexa Intramuscular Tossicita
Nessuna informazione disponibile
Zyprexa Intramuscular Informazioni paziente
PATIENT INFORMATION
Physicians are advised to discuss the following issues with patients for whom they prescribe
olanzapine:
Orthostatic Hypotension: Patients should be advised of the risk of orthostatic hypotension,
especially during the period of initial dose titration and in association with the use of
concomitant drugs that may potentiate the orthostatic effect of olanzapine, e.g., diazepam
or alcohol.
Interference with Cognitive and Motor Performance: Because olanzapine has the potential to
impair judgment, thinking, or motor skills, patients should be cautioned about operating
hazardous machinery, including automobiles, until they are reasonably certain that olanzapine
therapy does not affect them adversely.
Pregnancy: Patients should be advised to notify their physician if they become pregnant or
intend to become pregnant during therapy with olanzapine.
Nursing: Patients should be advised not to breast-feed an infant if they are taking olanzapine.
Concomitant Medication: Patients should be advised to inform their physicians if they are taking,
or plan to take, any prescription or over-the-counter drugs, since there is a potential for
interactions.
Alcohol: Patients should be advised to avoid alcohol while taking olanzapine.
Heat Exposure and Dehydration: Patients should be advised regarding appropriate care in avoiding
overheating and dehydration.
Phenylketonurics: ZYPREXA ZYDIS (olanzapine orally disintegrating tablets) contains phenylalanine
(0.34, 0.45, 0.67, or 0.90 mg per 5, 10, 15, or 20mg tablet, respectively).
Laboratory Tests
Periodic assessment of transaminases is recommended in patients with significant hepatic disease.
Physicians are advised to discuss the following issues with patients for whom they prescribe
olanzapine:
Orthostatic Hypotension: Patients should be advised of the risk of orthostatic hypotension,
especially during the period of initial dose titration and in association with the use of
concomitant drugs that may potentiate the orthostatic effect of olanzapine, e.g., diazepam
or alcohol.
Interference with Cognitive and Motor Performance: Because olanzapine has the potential to
impair judgment, thinking, or motor skills, patients should be cautioned about operating
hazardous machinery, including automobiles, until they are reasonably certain that olanzapine
therapy does not affect them adversely.
Pregnancy: Patients should be advised to notify their physician if they become pregnant or
intend to become pregnant during therapy with olanzapine.
Nursing: Patients should be advised not to breast-feed an infant if they are taking olanzapine.
Concomitant Medication: Patients should be advised to inform their physicians if they are taking,
or plan to take, any prescription or over-the-counter drugs, since there is a potential for
interactions.
Alcohol: Patients should be advised to avoid alcohol while taking olanzapine.
Heat Exposure and Dehydration: Patients should be advised regarding appropriate care in avoiding
overheating and dehydration.
Phenylketonurics: ZYPREXA ZYDIS (olanzapine orally disintegrating tablets) contains phenylalanine
(0.34, 0.45, 0.67, or 0.90 mg per 5, 10, 15, or 20mg tablet, respectively).
Laboratory Tests
Periodic assessment of transaminases is recommended in patients with significant hepatic disease.
Zyprexa Intramuscular Atto interessato organismi
Gli esseri umani e altri mammiferi
